Atezolizumab注射液 |进行中-招募完成

登记号
CTR20170061
相关登记号
曾用名
药物类型
生物制品
临床申请受理号
企业选择不公示
适应症
未接受过治疗的局部晚期或转移性尿路上皮癌
试验通俗题目
在尿路上皮癌患者中比较Atezolizumab和含铂化疗联合治疗的研究
试验专业题目
在未治疗的局部晚期或转移性尿路上皮癌患者中比较Atezolizumab和含铂化疗联合治疗的多中心、随机、安慰剂对照、III 期研究
试验方案编号
WO30070
方案最近版本号
V9
版本日期
2021-03-09
方案是否为联合用药
企业选择不公示

申请人信息

申请人名称
联系人姓名
丁侃
联系人座机
021-28923049
联系人手机号
联系人Email
stella.ding@roche.com
联系人邮政地址
上海市-上海市-龙东大道1100号11号楼3楼
联系人邮编
201203

临床试验信息

试验分类
有效性
试验分期
III期
试验目的
这是一项III 期、多中心、随机、安慰剂对照、部分设盲研究, 旨在评价Atezolizumab 单药治疗或与含铂化疗联合治疗对比安慰剂与含铂化疗联合治疗在既往未接受全身治疗的局部晚期或转移性尿路上皮癌患者中的有效性。
随机化
随机化
盲法
双盲
试验范围
国际多中心试验
设计类型
平行分组
年龄
18岁(最小年龄)至 无岁(最大年龄)
性别
男+女
健康受试者
入选标准
  • 签署知情同意
  • 年龄≥18 岁
  • 研究者认为患者适合接受含铂化疗
  • ECOG 体能状态评分≤2
  • 根据研究者的判断患者能够遵循研究方案
  • 组织学证实的局部晚期或转移性尿路上皮癌
  • 在入选研究前,为集中检测和确定肿瘤标本是否可进行肿瘤PD-L1 表达评价,患者需有代表性的福尔马林固定石蜡包埋肿瘤标本或至少15块未染色的肿瘤组织切片,以及相关的病理报告。
  • 既往对于不能手术的局部晚期或转移性尿路上皮癌未使用化疗
  • 按实体瘤疗效评价标准第1.1 版,具有可测量疾病
  • 足够的血液学和终末器官功能,按下述实验室检查结果定义,这些检查结果需在首次接受治疗前28天内获得。
  • 中性粒细胞绝对计数≥1500 个细胞/μL
  • 白细胞(WBC)计数> 2500 个细胞/μL
  • 淋巴细胞计数≥ 300 个细胞/μL
  • 血小板计数≥100,000 个细胞/μL
  • 血红蛋白≥ 9.0 g/dL
  • 天冬氨酸氨基转移酶、丙氨酸氨基转移酶和碱性磷酸酶≤2.5 × 正常上限(ULN)
  • 血清胆红素≤ 1.5 × ULN
  • 肌酐清除率≥30mL/min
  • 血清钙≤3 mmol/L
  • 对于育龄期妇女:同意在治疗期间以及末剂卡铂、顺铂、或吉西他滨给药后至少6 个月或者末剂Atezolizumab 给药后至少5 个月内保持禁欲(避免异性性交)或采取年失败率<1%的避孕措施
  • 对于男性:同意禁欲(避免异性性交)或采取避孕措施,并同意避免捐精。
排除标准
  • 开始研究治疗前3 周内接受任何已批准的抗癌治疗(包括化疗或激素疗法)
  • 入组前28 天内,接受了其他试验药物治疗或参与其他治疗目的的临床研究
  • 筛选期和影像学评估前,经计算机断层扫描(CT)或核磁共振成像(MRI)检测发现活动性或未治疗的CNS 转移灶
  • 软脑膜疾病
  • 未控制的胸腔积液、心包积液,或需要反复引流的腹水(每月一次或更频繁)
  • 未控制的肿瘤相关疼痛
  • 未控制的高钙血症
  • 第1 疗程第1 天前5 年内患有尿路上皮癌以外的其他恶性肿瘤
  • 预期寿命<12 周
  • 处于妊娠期、哺乳期或计划在研究期间怀孕
  • 血清白蛋白< 25 g/L
  • 对嵌合或人源化抗体或融合蛋白有严重过敏、过敏反应或其他超敏反应病史
  • 已知对由中国仓鼠卵巢细胞生产的生物药品或Atezolizumab 制剂任何成分过敏或有超敏反应
  • 自身免疫性疾病病史,包括但不限于重症肌无力、肌炎、自身免疫性肝炎、系统性红斑狼疮、类风湿性关节炎、炎性肠病、抗磷脂综合征相关的血管血栓形成、Wegener's 肉芽肿病、干燥综合征、格林-巴利综合征、多发性硬化、血管炎、肾小球肾炎等。
  • 既往接受过异体干细胞移植或实体器官移植的患者
  • 有特发性肺纤维化病史(包括肺炎)、药物诱导性肺炎病史、机化性肺炎病史(即,闭塞性细支气管炎,隐源性机化性肺炎),或筛选期胸部CT 扫描发现活动性肺炎证据
  • 重大心血管疾病,如纽约心脏病学会定义的心脏疾病(III 级或更高)、随机分配前3月内发生的心肌梗塞、不稳定型心律失常、不稳定型心绞痛
  • 左心室射血分数(LVEF)< 40%
  • HIV 检测结果呈阳性
  • 活动性乙型肝炎(定义为筛选期乙肝病毒表面抗原[HBsAg]检测结果阳性)或丙型肝炎
  • 活动性肺结核
  • 随机入组前4 周内发生重度感染,包括但不限于因感染、菌血症或重度肺炎等并发症而入院治疗的情况。
  • 随机入组前2 周内接受口服或静脉途径的抗生素治疗
  • 随机分配前4 周内接受过大型手术,或预期将在研究期间接受大型手术(以诊断为目的的手术除外)
  • 在第1 疗程第1 天前4 周内使用了减毒活疫苗
  • 任何其它疾病、代谢障碍、体格检查结果或临床实验室检查异常结果,并有理由怀疑可能导致禁忌使用试验药物、或影响研究结果可靠性、或使患者处于高风险的治疗并发症的疾病或病症
  • 既往接受过CD137 激动剂、抗CTLA-4、抗PD-1 或抗PD-L1 治疗性抗体或信号通路靶向药物治疗
  • 在第1 疗程第1 天前4 周内或药物5 个半衰期内(以短者为准)接受过全身免疫刺激剂治疗(包括但不限于干扰素或白介素-2)
  • 第1 疗程第1 天前2 周内接受过全身性皮质类固醇或其他全身免疫抑制药物(包括但不限于泼尼松、地塞米松、环磷酰胺、硫唑嘌呤、甲氨喋呤、沙利度胺、抗肿瘤坏死因子[TNF] 制剂),或者预期在研究期间需要使用全身免疫抑制药物
  • 已知对吉西他滨存在超敏反应史
  • 存在严重的顺铂、或其它含铂化合物过敏反应史
  • 重度骨髓抑制或严重出血
  • 顺铂禁用于既存肾功能损害的患者。骨髓抑制或听力受损患者不应使用顺铂
  • 顺铂禁用于存在顺铂或其他含铂化合物过敏反应史的患者

试验分组

试验药
名称 用法
中文通用名:Atezolizumab注射液
用法用量:注射液;规格1200mg/20ml;静脉注射,每3周一次,每次1200mg,治疗将持续直到失去临床获益、不可耐受的毒性、患者或医生决定中止治疗、或接受试验治疗的患者死亡。
对照药
名称 用法
中文通用名:安慰剂注射液
用法用量:注射液;规格1200mg/20ml;静脉注射,每3周一次,每次1200mg,用药时程:直至研究者按实体瘤疗效评价标准第1.1 版判定患者出现疾病进展或不可耐受的毒性反应。
中文通用名:吉西他滨注射液 英文名:Gemcitabine 商品名:健择
用法用量:注射液;规格 200mg;静脉注射,起始剂量为1000 mg/m2,在每个21天疗程的第1 天和第8 天经静脉输注给药,用药时程:直至研究者按实体瘤疗效评价标准第1.1 版判定患者出现疾病进展或不可耐受的毒性反应。
中文通用名:卡铂注射液 英文名:Carboplatin 商品名:伯尔定
用法用量:注射液;规格 150mg/15ml;静脉注射,将计算卡铂的起始剂量,以使得AUC 达到4.5,在每个21 天疗程的第1 天经静脉输注给药,用药时程:直至研究者按实体瘤疗效评价标准第1.1 版判定患者出现疾病进展或不可耐受的毒性反应。
中文通用名:顺铂注射液 英文名:Cisplatin 商品名:顺铂
用法用量:注射液;规格 50mg/50ml;静脉注射,顺铂的起始剂量为70mg/m2,在每个21 天疗程的第1 天经静脉输注给药,用药时程:直至研究者按实体瘤疗效评价标准第1.1 版判定患者出现疾病进展或不可耐受的毒性反应。

终点指标

主要终点指标
指标 评价时间 终点指标选择
研究者按照RECIST v1.1 评估的无进展生存期和总生存期。 44个月 有效性指标
次要终点指标
指标 评价时间 终点指标选择
客观缓解率,缓解持续时间,Atezolizumab 单药治疗患者对比安慰剂+含铂化疗患者中研究者评估的无进展生存期,1 年OS 率,1 年PFS 率,根据欧洲癌症研究和治疗组织(EORTC)生活质量调查问卷核心30(QLQ-C30)测 量的至总体健康状态恶化的时间和EORTC QLQ-C30 测定的身体机能恶化的时间。 44个月 有效性指标
数据安全监察委员会(DMC)
为受试者购买试验伤害保险

研究者信息

姓名 学位 职称 电话 Email 邮政地址 邮编 单位名称
叶定伟 医学博士 主任医师 13701663571 dwyeli@163.com 上海市-上海市-东安路270号 200032 复旦大学附属肿瘤医院

各参加机构信息

机构名称 (主要)研究者 国家 地区 城市
复旦大学附属肿瘤医院 叶定伟 中国 上海市 上海市
首都医科大学附属北京友谊医院 田野 中国 北京市 北京市
中山大学孙逸仙纪念医院 黄健 中国 广东省 广州市
江苏省肿瘤医院 邹青 中国 江苏省 南京市
复旦大学附属中山医院 郭剑明 中国 上海市 上海市
中国医学科学院北京协和医院 纪志刚 中国 北京市 北京市
重庆肿瘤医院 罗宏 中国 重庆市 重庆市
上海华东医院 孙忠全 中国 上海市 上海市
Ashford Cancer Center Research FRANCIS PARNIS AUSTRALIA South Australia Kurralta Park
Box Hill Hospital Ian Davis AUSTRALIA Victoria Box Hill
CABRINI MEDICAL CENTRE; ONCOLOGY JEREMY SHAPIRO AUSTRALIA Victoria MALVERN
Macquarie University Hospital HOWARD GURNEY AUSTRALIA New South Wales Macquarie University
Royal Women Hospital Aneta Suder AUSTRALIA Queensland Herston
Sunshine Hospital Oncology Research Shirley Wong AUSTRALIA Victoria St Albans
Macquarie University Hospital HOWARD GURNEY AUSTRALIA New South Wales Westmead
AZ Sint Lucas (Sint Lucas) Vincent Renard BELGIUM GENT GENT
CHC MontLégia Marie-Pascale Graas BELGIUM Liege Liege
GHdC Site Notre Dame Marco Gizzi BELGIUM Charleroi Charleroi
UZ Leuven Gasthuisberg Herlinde Dumez BELGIUM Leuven Leuven
Clinic of Oncology University Clinical Center Timur Ceric BOSNIA SARAJEVO SARAJEVO
University Clinical Centre SASA JUNGIC BOSNIA BANJA LUKA BANJA LUKA
CETUS Hospital Dia Oncologia Bruno Aragao BRAZIL MG Belo Horizonte
Clinica de Neoplasias Litoral Giuliano Borges BRAZIL SC Itajai
Clinicas Oncologicas Integradas Monica Padoan BRAZIL RJ Rio de Janeiro
Clinica Viver Luis Antunes BRAZIL RS SANTA MARIA
Hospital das Clinicas Rodrigo Pereira BRAZIL RS Porto Alegre
Hospital de Base de Sao Jose do Rio Preto Gustavo Girotto BRAZIL SP Sao Jose do Rio Preto
Hospital de Caridade de Ijui Oncologia Fabio Andre Franke BRAZIL RS Ijui
Hospital Nossa Senhora da Conceicao Carlos Gorini BRAZIL RS Porto Alegre
Hospital Sao Lucas - PUCRS Andre Fay BRAZIL RS Porto Alegre
Instituto do Cancer do Estado de Sao Paulo - ICESP Diogo Bastos BRAZIL SP Sao Paulo
Cross Cancer Institute SCOTT NORTH CANADA Alberta EDMONTON
Dr. Léon-Richard Oncology Centre ALI BENJELLOUN CANADA New Brunswick Moncton
Juravinski Cancer Clinic Clinical Trials Department SOM MUKHERJEE CANADA Ontario HAMILTON
Lakeridge Health Center R. S. MacLaughlin Durham Regional Cancer Center Pawel Zalewski CANADA Ontario OSHAWA
NORTH YORK GENERAL HOSPITAL Danny Robson CANADA Ontario TORONTO
Tom Baker Cancer Centre-Calgary Clinical Research Unit Nimira Alimohamed CANADA Alberta Calgary
Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas Mauricio Burotto CHILE RECOLETA RECOLETA
Health & Care SPA FRANSCICO ORLANDI CHILE NE Grand Island
Clinica Alemana Claudio Salas CHILE Vitacura Vitacura
Fundacion Arturo Lopez Perez PAMELA SALMAN CHILE Santiago Santiago
Masarykuv onkologicky ustav Alexandr Poprach CZECH REPUBLIC Toscana PISA
University Hospital Motol Department of Urology Marek Babjuk CZECH REPUBLIC Praha 5 Praha 5
Vseobecna fakultni nemocnice v Praze Milada Zemanova CZECH REPUBLIC PRAHA 2 PRAHA 2
East Tallinn Central Hospital Kristiina Ojamaa ESTONIA Tallinn Tallinn
North Estonia Medical Centre Foundation; Oncology Center Helis Pokker ESTONIA Tallinn Tallinn
OULU UNIVERSITY HOSPITAL ONCOLOGY Minna Jaaskeluinen FINLAND OULU OULU
TURKU UNI CENTRAL HOSPITAL; ONCOLOGY CLINICS Johanna Ruohola FINLAND Turku Turku
Chemotherapy Clinic Giorgi Adeishvili GEORGIA Tbilisi Tbilisi
National Center of Urology Ambrosi Pertia GEORGIA TBILISI TBILISI
Research institute for Clinical Medicine Zaal Kvirikashvili GEORGIA Tbilisi Tbilisi
Alexandras General Hospital of Athens Oncology Department Aristotelis Bamias GREECE Athens Athens
UNIVERSITY HOSPITAL OF PATRAS MEDICAL ONCOLOGY HARALABOS KALOFONOS GREECE Patras Patras
PRINCESS MARGARET HOSPITAL ONCOLOGY CHI KIN CHENG 中国香港 HONG KONG HONG KONG
QUEEN ELIZABETH HOSPITAL CLINICAL ONCOLOGY Ho Ching Lam 中国香港 HONG KONG HONG KONG
QUEEN MARY HOSPITAL DEPT OF CLINICAL ONCOLOGY Steven Siu 中国香港 HONG KONG HONG KONG
The Chinese University of Hong Kong Department of Clinical Oncology Darren Poon 中国香港 HONG KONG HONG KONG
Rambam Health Care Campus Oncology Avivit Peer ISRAEL Haifa Haifa
A.O CITTA' DELLA SALUTE E DELLA SCIENZA D. - Presidio San Lazzaro; Oncologia medica 2 MARIO AIROLDI ITALY Piemonte TORINO
A.O. Universitaria Policlinico Di Modena; Oncologia Roberto Sabbatini ITALY Emilia-Romagna MODENA
ASST DI CREMONA; Dip. Medicina - S.C. Oncologia RODOLFO PASSALACQUA ITALY Lombardia CREMONA
Azienda Ospedaliera A. Cardarelli; Dip. Oncopneumoematologico Ferdinando Riccardi ITALY Campania Napoli
Azienda Ospedaliera S. Maria - Terni; Oncologia Claudia Caserta ITALY Umbria Terni
Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia Alketa Hamzaj ITALY Toscana Arezzo
IRCCS ISTITUTO NAZIONALE DEI TUMORI (INT);S.C. MEDICINA ONCOLOGICA 2 Andrea Necchi ITALY Lombardia MILANO
IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima Umberto Basso ITALY Veneto PADOVA
IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia Franco Morelli ITALY Puglia SAN GIOVANNI ROTONDO
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica Ugo De Giorgi ITALY Emilia-Romagna Meldola
ISTITUTO CLINICO HUMANITAS;U.O. ONCOLOGIA MEDICA ED EMATOLOGIA Paolo Zucali ITALY Lombardia ROZZANO
Policlinico Umberto i di Roma; dip. Scienze Radiologiche, Oncologiche, Anatomopatologiche ENRICO CORTESI ITALY Lazio ROMA
Gunma University Hospital Kazuhiro Suzuki JAPAN Gunma Gunma
Hirosaki University Hospital Yasuhiro Hashimoto JAPAN Aomori Aomori
Kanazawa University Hospital Kouji Izumi JAPAN Ishikawa Ishikawa
Keio University Hospital Ryuichi Mizuno JAPAN Tokyo Tokyo
Kindai University Hospital Kazuhiro Yoshimura JAPAN Osaka Osaka
Kumamoto University Hospital Takahiro Yamaguchi JAPAN Kumamoto Kumamoto
Nagoya University Hospital Takashi Fujita JAPAN Aichi Aichi
National Hospital Organization Hokkaido Cancer Center Satoshi Nagamori JAPAN Hokkaido Hokkaido
National Hospital Organization Shikoku Cancer Center Katsuyoshi Hashine JAPAN Ehime Ehime
Niigata University Medical & Dental Hospital Yoshihiko Tomita JAPAN Niigata Niigata
Osaka City University Hospital Satoshi Tamada JAPAN Osaka Osaka
The Cancer Institute Hospital, JFCR; Urology Junji Yonese JAPAN Tokyo Tokyo
Toranomon Hospital Yuji Miura JAPAN Tokyo Tokyo
University of Tsukuba Hospital Tomokazu Kimura JAPAN Ibaraki Ibaraki
Gachon University Gil Medical Center YoungSaing Kim KOREA, REPUBLIC OF Incheon Incheon
Korea University Anam Hospital Kyong Hwa Park KOREA, REPUBLIC OF Seoul Seoul
Kyungpook National University Medical Center JONG GWANG KIM KOREA, REPUBLIC OF Daegu Daegu
Samsung Medical Center Se Hoon Park KOREA, REPUBLIC OF Seoul Seoul
Seoul National University Hospital Bhumsuk Keam KOREA, REPUBLIC OF Seoul Seoul
Severance Hospital, Yonsei University Health System Sang-Joon Shin KOREA, REPUBLIC OF Seoul Seoul
Hospital Kuala Lumpur; Jabatan Radioterapi dan Onkologi Muthukkumaran Thiagarajan MALAYSIA Kuala Lumpur Kuala Lumpur
University Malaya Medical Centre; Clinical Oncology Unit, Marniza Saad MALAYSIA Kuala Lumpur Kuala Lumpur
Cancerología ADRIANA DOMINGUEZ MEXICO QUERETARO Queretaro
Consultorio Médico José Arturo Rodríguez MEXICO Zapopan, Jalisco Zapopan, Jalisco
Health Pharma Professional Research Perla Perez MEXICO MEXICO CITY (FEDERAL DISTRICT) CD Mexico
Hospital San Jose; Centro de investigacion y transferencia en salud del Tec de Monterrey Jorge Luis Martinez Rodriguez MEXICO Monterrey, N.L Monterrey, N.L
IMSS Hospital General de Zona No. 48 S. Pedro Xalpa; Departamento de Urología Noel Amaro MEXICO Ciudad de México DF Ciudad de México DF
Hagaziekenhuis, locatie Leyweg Danny Houtsma NETHERLANDS NL -DEN HAAG NL -DEN HAAG
Zuyderland Medisch Centrum; Internal Diseases Franchette Van Den Berkmortel NETHERLANDS Sittard-Geleen Sittard-Geleen
Bialostockie Centrum Onkologii; Oddzial Onkologii Klinicznej MAREK WOJTUKIEWICZ POLAND BIALYSTOK BIALYSTOK
NU-MED Centrum Diagnostyki i Terapii Onkologicznej EWA CHMIELOWSKA POLAND Tomaszów Mazowiecki Tomaszów Mazowiecki
Oddzial Chemioterapii Szpitala Klinicznego Nr 1 w Poznaniu PIOTR TOMCZAK POLAND Poznan Poznan
Przychodnia Lekarska KOMED, Roman Karaszewski Bogus?awa Karaszewska POLAND Konin Konin
Szpital Sw. Elzbiety - Mokotowskie Centrum Medyczne Sp. z o.o. Iwona Skoneczna POLAND Warszawa Warszawa
Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii Piotr Wysocki POLAND Kraków Kraków
Woj.Wielospecjalistyczne Centrum Onkologii i Traumatologii; Oddz.Hematologii Pododz.Chemioterapii Piotr Potemski POLAND Lodz Lodz
Hospital de Santa Maria; Servico de Oncologia Medica Isabel Fernandes PORTUGAL LISBOA LISBOA
IPO do Porto; Servico de Oncologia Medica Nuno Sousa PORTUGAL PORTO PORTO
Institute Of Oncology Bucharest; Medical Oncology Dana Lucia Stanculeanu ROMANIA Bucharest Bucharest
Oncology Center Sf. Nectarie Michael Schenker ROMANIA Craiova Craiova
Spitalul Judetean de Urgenta Dr Constantin Opris Amalia Alina Herzal ROMANIA Baia Mare Baia Mare
ALTAI REGIONAL ONCOLOGICAL CENTER; Sergey Varlamov RUSSIAN FEDERATION BARNAUL BARNAUL
BLOKHIN CANCER RESEARCH CENTER; UROLOGICAL DEPT Vsevolod Matveev RUSSIAN FEDERATION MOSCOW MOSCOW
Ivanovo Regional Oncology Dispensary Andrey Semenov RUSSIAN FEDERATION Ivanovo Ivanovo
Krasnoyarsk Regional Oncology Dispensary n.a. Krizhanovsky; Chemotherapy Ruslan Zukov RUSSIAN FEDERATION Krasnoyarsk Krasnoyarsk
P.A. HERZEN ONCOLOGICAL INST. ; ONCOLOGY Boris Alekseev RUSSIAN FEDERATION MOSCOW MOSCOW
PRIVOLZHSK REGIONAL MEDICAL CENTER Vagif Atduev RUSSIAN FEDERATION NIZHNY NOVGOROD NIZHNY NOVGOROD
Russian Scientific Center of Roentgenoradiology Rustem Gafanov RUSSIAN FEDERATION Moscow Moscow
SBEI HPE Salman Al-Shukri RUSSIAN FEDERATION ST PETERSBURG ST PETERSBURG
SBEI of HPE “Bashkir State Medical University” of MoH RF Adel Izmaylov RUSSIAN FEDERATION Ufa Ufa
Scientific Research Oncology Institute named after N.N. Petrov; Oncology Alexander Nosov RUSSIAN FEDERATION St. Petersburg St. Petersburg
Sverdlovsk Regional Clinical Hospital 1 Dmitry Tevs RUSSIAN FEDERATION EKATERINBURG EKATERINBURG
Clinical Center of Serbia; Clinic of Urology Zoran Dzamic SERBIA BELGRADE BELGRADE
Clinical Centre Nis, Clinic for Oncology Vesna Stojanovic SERBIA NIs NIs
Oncology Institute of Vojvodina Lazar Popovic SERBIA Sremska Kamenica Sremska Kamenica
NATIONAL CANCER CENTRE; MEDICAL ONCOLOGY Ravindran Kanesvaran SINGAPORE Singapore Singapore
National University Hospital; National University Cancer Institute, Singapore (NCIS) Alvin Wong SINGAPORE Singapore Singapore
Oncocare Cancer Centre; Gleneagles Medical Centre MIAH HIANG TAY SINGAPORE Singapore Singapore
INSTITUTE OF ONCOLOGY LJUBLJANA Marina Mencinger SLOVENIA LJUBLJANA LJUBLJANA
Cancercare Jorn Malan SOUTH AFRICA Port Elizabeth Port Elizabeth
Sandton Oncology Medical Group Sze Chan SOUTH AFRICA Sandton Sandton
Steve Biko Academic Hospital; Oncology LYDIA DREOSTI SOUTH AFRICA Pretoria Pretoria
Hospital Universitario 12 de Octubre; Servicio de Oncologia Daniel Castellano SPAIN Toscana PISA
Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia Pablo Maroto Rey SPAIN Toscana PISA
Clinica Universitaria de Navarra; Servicio de Oncologia Jose Luis Perez Gracia SPAIN NAVARRA PAMPLONA
Complejo Asistencial Universitario De Burgos; Servicio de Oncologia Guillermo Crespo Herrero SPAIN BURGOS Burgos
Complejo Asistencial Universitario de Leon; Servicio de Oncologia Angel Rodríguez Sánchez SPAIN LEON LEON
Complejo Hospitalario de Althaia; Servicio de Oncologia Montserrat Domenech Santasusana SPAIN BARCELONA MANRESA
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia Esther Martínez SPAIN JAEN JAEN
Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia Iciar Garcia Carbonero SPAIN TOLEDO TOLEDO
Complejo Hospitalario Universitario de Albacete; Servicio de Oncologia Esther Nogueron Martinez SPAIN ALBACETE ALBACETE
Corporacio Sanitaria Parc Tauli; Servicio de Oncologia Enrique Gallardo Diaz SPAIN BARCELONA Sabadell
Hospital Alvaro Cunqueiro Emilio Martin Lazaro Quintela SPAIN PONTEVEDRA Vigo
Hospital Clinic de Barcelona. Unidad de Nuevas Terapias;Oncology Department Bego?a Mellado Gonzalez SPAIN BARCELONA Barcelona
Hospital Clinico Universitario Lozano Blesa; Servicio de Oncologia Eduardo Pujol SPAIN ZARAGOZA Zaragoza
Hospital de Basurto; Servicio de Oncologia Teresa Abad Villar SPAIN VIZCAYA BILBAO
Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia Pablo Maroto Rey SPAIN BARCELONA Barcelona
Hospital General Universitario de Elche; Servicio de Oncologia Federico Vazquez Mazon SPAIN ALICANTE ELCHE
Hospital General Universitario Gregorio Mara?on; Servicio de Oncologia Jose Angel Arranz Arija SPAIN MADRID Madrid
Hospital Juan Ramon Jimenez;Servicio de Oncologia Francisco Jose Alvarez Marquez SPAIN HUELVA HUELVA
Hospital Provincial de Castellon; Servicio de Oncologia Alfredo Sanchez Hernandez SPAIN CASTELLON CASTELLON
Hospital Ramon y Cajal; Servicio de Oncologia Pablo Gajate Borau SPAIN MADRID Madrid
Hospital San Pedro De Alcantara; Servicio de Oncologia Ricardo Collado Martin SPAIN CACERES Caceres
HOSPITAL UNIVERSITARIO SON ESPASES Maria del Carmen Garcias de Espa?a SPAIN ISLAS BALEARES PALMA DE MALLORCA
Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia Albert Font Pous SPAIN BARCELONA Barcelona
Hospital Universitario 12 de Octubre; Servicio de Oncologia Daniel Castellano SPAIN MADRID MADRID
Hospital Universitario Clínico San Carlos; Servicio de Oncologia Javier Puente Vazquez SPAIN MADRID MADRID
Hospital Universitario la Fe; Servicio de Oncologia Regina Girones Sarrio SPAIN VALENCIA VALENCIA
Hospital Universitario La Paz; Servicio de Oncologia Alvaro Pinto Marin SPAIN MADRID MADRID
Hospital Universitario Lucus Augusti Sergio Vazquez Estevez SPAIN LUGO LUGO
Hospital Universitario Marques de Valdecilla; Servicio de OncologiaHospital Universitario Marques de Valdecilla; Servicio de Oncologia Marta Lopez-Brea Piqueras SPAIN CANTABRIA SANTANDER
Hospital Universitario Miguel Servet; Servicio de Oncologia Medica M. Del Carmen Santander Lobera SPAIN ZARAGOZA ZARAGOZA
Hospital Universitario Reina Sofia; Servicio de Oncologia Ma JOSE MENDEZ SPAIN CORDOBA CORDOBA
HOSPITAL UNIVERSITARIO SON ESPASES Maria del Carmen Garcias de Espafla SPAIN ISLAS BALEARES Palma De Mallorca
Hospital Universitario Virgen de las Nieves; Servicio de Oncologia Raquel Luque Caro SPAIN GRANADA GRANADA
Hospital Universitario Servicio Oncologia Bega Perez Valderrama SPAIN SEVILLA SEVILLA
Hospital Univ Vall Servicio de Oncologia Rafael Morales Barrera SPAIN BARCELONA BARCELONA
Institutio Catalan De Oncologia Xavier Garcia del Muro SPAIN BARCELONA BARCELONA
Chang Gung Medical Foundation - Kaohsiung; Oncology Yu-Li Su 中国台湾 Kaohisung Kaohisung
Chang Gung Medical Foundation-Linkou, Urinary Oncology Cheng-Keng 中国台湾 TAOYUAN TAOYUAN
China Medical University Hospital; Urology Su-Peng Yeh 中国台湾 Taichung Taichung
NATIONAL UNI HOSPITAL Wen-Pin Su 中国台湾 TAINAN TAINAN
NATIONAL TAIWAN UNI HOSPITAL; DEPT OF ONCOLOGY Yu-Chieh Tsai 中国台湾 Taipei City Taipei City
TAICHUNG VETERANS GENERAL HOSPITAL; DIVISION OF UROLOGY Jian-Ri Li 中国台湾 TAICHUNG TAICHUNG
CHULALONGKORN HOSPITAL; MEDICAL ONCOLOGY VIROTE SRIURANPONG THAILAND BANGKOK BANGKOK
FACULTY OF MED ONCOLOGY Pongwut Danchaivijitr THAILAND BANGKOK BANGKOK
Maharaj Nakorn Chiang Mai Hospital; Department of Medicine Chaiyut Charoentum THAILAND ChiangMai ChiangMai
Vajira Hospital Yotsawaj Runglodvatana THAILAND Dusit Dusit
RAMATHIBODI HOSPITAL Phichai Chansriwong THAILAND BANGKOK BANGKOK
Medical Faculty; Medical Oncology Department Bahiddin lmaz TURKEY samsun samsun
Ankara City Hospital Mehmet Ali Nahit Sendur TURKEY Ankara Ankara
Research Hospital Medical Oncology Fatih Kose TURKEY ADANA ADANA
University Medical School; Oncology Hac Mehmet Turk TURKEY Istanbul Istanbul
UNI MEDICAL FACULTY HOSPITAL Mustafa Erman TURKEY ANKARA ANKARA
Medical Oncology Department MUSTAFA OZGUROGLU TURKEY ISTANBUL ISTANBUL
Diseases Research Hospital Mahmut Gumus TURKEY ISTANBUL ISTANBUL
Medical Park Hospital Cagatay Arslan TURKEY Kar?yaka Kar?yaka
Medical Onology Hospital Irfan Cicin TURKEY Edirne Edirne
Oncology Disease Hospital IGOR BONDARENKO UKRAINE Dnipropetrovsk Dnipropetrovsk
Regional Clinical Center Igor Antonyan UKRAINE GOVERNORATE Kharkiv
BEATSON WEST OF SCOTLAND CANCER CENTRE Robert Jones UNITED KINGDOM GLASGOW GLASGOW
The York Hospital Joji Joseph UNITED KINGDOM York York
University College London Hospitals NHS Foundation Trust - University College Hospital Ursula McGovern UNITED KINGDOM London London
Bon Secours - St. Francis Hospital Stephen Dyar UNITED STATES SC Greenville
Christina Care Institutional Review Board MICHAEL GUARINO UNITED STATES DE Newark
Coastal Integrative Cancer Care Thomas John Spillane UNITED STATES CA San Luis Obispo
COMPREHENSIVE CANCER CENTERS OF NEVADA Nicholas Vogelzang UNITED STATES NV LAS VEGAS
East Jefferson Hematology Oncology; Hematology Oncology-Yenni Pavillion Thomas Cosgriff UNITED STATES LA METAIRIE
Florida Cancer Specialists; Department of Oncology James Reeves UNITED STATES FL Fort Myers
Florida Cancer Specialists (St. Petersburg – St. Anthony’s Professional Building) LUCIO GORDAN UNITED STATES FL Saint Petersburg
Highlands Oncology Group J. Thaddeus Beck UNITED STATES AR ROGERS
Moffitt Cancer Center; GME Office Jingsong Zhang UNITED STATES FL Tampa
Mount Sinai School of Medicine - Tisch Cancer Institute Matthew Galsky UNITED STATES NY New York
Norton Cancer Institute Chandler Park UNITED STATES KY Louisville
Norwalk Hospital Richard Frank UNITED STATES CT Norwalk
Park Nicollet Clin-Cancer Ctr Rachel Lerner UNITED STATES MN ST LOUIS PARK
Parkview Research Center Zhentao Zhang UNITED STATES IN Fort Wayne
Sarah Cannon Cancer Center Johanna Bendell UNITED STATES TN NASHVILLE
The University of Chicago Biological Sciences; Dept. of Medicine, Section of Hematology/Oncology Peter Donnell UNITED STATES IL Chicago
UF Health Cancer Center at Orlando Health Daniel Landau UNITED STATES FL Orlando
University of North Carolina, Lineberger Cancer Ctr Matthew Milowsky UNITED STATES NC Chapel Hill
Yale School of Medicine Daniel Petrylak UNITED STATES CT New Haven
天津医科大学附属第二医院 牛远杰 中国 天津市 天津市

伦理委员会信息

名称 审查结论 审查日期
江苏省肿瘤医院伦理委员会 同意 2016-12-29
复旦大学附属肿瘤医院医学伦理委员会 同意 2020-06-02
复旦大学附属肿瘤医院医学伦理委员会 同意 2022-07-20

试验状态信息

试验状态
进行中-招募完成
目标入组人数
国内: 240 ; 国际: 1200 ;
已入组例数
国内: 40 ; 国际: 1214 ;
实际入组总例数
国内: 登记人暂未填写该信息; 国际: 登记人暂未填写该信息;
第一例受试者签署知情同意书日期
国内:2017-06-28;     国际:2016-06-23;
第一例受试者入组日期
国内:2017-07-15;     国际:2016-06-27;
试验终止日期
国内:登记人暂未填写该信息;     国际:登记人暂未填写该信息;

临床试验结果摘要

版本号 版本日期

发布
问题